Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $16.2300 (-1.81%) ($15.9900 - $16.5600) on Tue. Apr. 11, 2017. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.13% (three month average) | RSI | 21 | Latest Price | $16.2300(-1.81%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -0.6% a day on average for past five trading days. | Weekly Trend | ADMS declines -2.5% a week on average for past two weeks. | Market Behavior | Growth stock sell-off for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XBI(25%) IBB(22%) ARKG(18%) IWO(18%) XOP(18%) | Factors Impacting ADMS price | ADMS will decline at least -1.065% in a week (0% probabilities). VIXM(-11%) UUP(-10%) UNG(-8%) BNDX(-7%) TLT(-5%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.065% (StdDev 2.13%) | Hourly BBV | 0 () | Intraday Trend | -1.5% | | | |
|
1 - 5 Day Possible Target | $12.27(-24.4%) | Resistance Level | $17.18 | 5 Day Moving Average | $16.63(-2.41%) | 10 Day Moving Average | $16.89(-3.91%) | 20 Day Moving Average | $17.18(-5.53%) | To recent high | -12.3% | To recent low | 9.1% | Market Cap | $459m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |